Paladin Partners’s Medifast MED Stock Holding History

Paladin Partners’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318	Hold	30	–	–	﹤0.01%	207
2026 Q1	$306	Hold	30	–	–	﹤0.01%	205
2025 Q4	$320	Buy	+30	New	+$359	﹤0.01%	208

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Paladin Partners's MED Position: Q2 2026 in Review

Paladin Partners held its Medifast (MED) position steady in Q2 2026 at 30 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #207.

Paladin Partners first reported a position in MED in Q4 2025 and has held it in 3 quarters since. The position peaked at $320 in Q4 2025. 113 funds tracked by Wall St. Rank hold MED as of Q2 2026.

Paladin Partners held 30 shares of Medifast worth $318 as of Q2 2026.
Paladin Partners left its Medifast share count unchanged in Q2 2026.
Medifast made up ﹤0.01% of Paladin Partners's portfolio in Q2 2026, its #207 holding.
Paladin Partners first reported a position in Medifast in Q4 2025 and has held it in 3 quarters since.
Paladin Partners's Medifast position peaked at $320 in Q4 2025.
113 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.